A Study of Ponesimod in Healthy Adult Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-18

Study Completion Date

2023-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of steady-state carbamazepine (CBZ; a strong pregnane X receptor \[PXR\] agonist) on the pharmacokinetics (PK) of ponesimod following a gradual up-titration regimen in healthy adult participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time

NCT00809536

Generalized Anxiety Disorder

TERMINATED PHASE1

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

NCT02708394

Adverse Effect of Other Antipsychotics and Neuroleptics Insulin Resistance

COMPLETED EARLY_PHASE1

An Insulin Sensitivity Study in Healthy Subjects

NCT02922426

Healthy Volunteers

COMPLETED PHASE1

Pharmacoepigenetics of Bipolar Disorder Treatment

NCT02374996

Antipsychotic Agents Bipolar Disorder

COMPLETED

Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population

NCT04395326

Adverse Drug Event

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A: Ponesimod

Participants will receive up-titrated Ponesimod orally once daily from Day 1 to Day 15.

Group Type EXPERIMENTAL

Ponesimod

Intervention Type DRUG

Ponesimod tablet will be administered orally.

Treatment B: Ponesimod + Carbamazepine

Participants will receive up-titrated Carbamazepine from Day 1 to Day 7 and from Day 23 to Day 26. Participants will also receive up-titrated Ponesimod and Carbamazepine from Day 8 to Day 22.

Group Type EXPERIMENTAL

Ponesimod

Intervention Type DRUG

Ponesimod tablet will be administered orally.

Carbamazepine

Intervention Type DRUG

Carbamazepine tablet will be administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ponesimod

Ponesimod tablet will be administered orally.

Intervention Type DRUG

Carbamazepine

Carbamazepine tablet will be administered orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JNJ-67896153 ACT-128800 Ponvory Tegretol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index between (BMI) 18-30 kilograms per meter square (kg/m\^2)
* Willing and able to adhere to the prohibitions and restrictions.
* Female participants with negative pregnancy test.
* Women of childbearing potential (WOCBP) must use 2 methods of contraception.
* Healthy on the basis of physical examination (including neurological examination and skin examination), Columbia suicide severity rating scale questionnaire (C-SSRS) questionnaire, ophthalmological examination, medical history, vital signs, and 12-lead electrocardiogram (ECG).
* Positive varicella zoster virus (VZV).

Exclusion Criteria

* History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below 60 milliliter per minute \[mL/min\]), thyroid disease, neurologic or psychiatric disease, confirmed or suspected macular edema, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results.
* Contraindications to the use of Carbamazepine (CBZ) as per local prescribing information
* Any immunosuppressive treatment within 6 weeks before first study drug administration.
* Lymphopenia (less than 1,000 cells per microliter).
* Received an investigational drug or used an invasive investigational medical device within 30 days before the first study drug intake or received a biological product within 3 months or 5 half-lives (whichever is longer) before the first study drug intake, or is currently enrolled in an investigational study.
* Lack of good/reasonable venous access.
* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes